Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting Eisai Mar 31, 2023 15:51 HKT/SGT Read More
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals Eisai Mar 31, 2023 13:55 HKT/SGT Read More
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer Eisai Mar 24, 2023 12:22 HKT/SGT Read More
エーザイ、米国婦人科腫瘍学会（SGO）2023 Annual Meeting on Women's Cancerにおいてオンコロジー領域の臨床研究の演題を発表 Eisai Mar 24, 2023 11:00 JST Read More
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting Eisai Mar 23, 2023 12:30 HKT/SGT Read More
エーザイ、第17回アルツハイマー・パーキンソン病学会（AD/PD 2023）において、レカネマブの安全性プロファイル、臨床結果、QOLの評価など、アルツハイマー病の研究に関する最新情報を発表 Eisai Mar 23, 2023 09:00 JST Read More
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal Eisai Mar 20, 2023 10:18 HKT/SGT Read More
エーザイ、臨床第III相 Clarity AD 試験データを用いた「レカネマブ」の社会的価値について、査読学術専門誌 Neurology and Therapy 誌に掲載 Eisai Mar 20, 2023 10:00 JST Read More
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease Eisai Mar 14, 2023 10:09 HKT/SGT Read More
エーザイ、早期アルツハイマー病治療薬「LEQEMBI(TM)」（レカネマブ）について、米国退役軍人保健局が FDA による迅速承認から 2 カ月で保険適用を開始 Eisai Mar 14, 2023 09:30 JST Read More
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award Eisai Mar 10, 2023 14:04 HKT/SGT Read More
Eisai Certified as a 2023 Health and Productivity Management Outstanding Eisai Mar 09, 2023 08:07 HKT/SGT Read More
エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請（sBLA）が米国FDAに受理され、優先審査に指定 Eisai Mar 06, 2023 10:00 JST Read More
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease Eisai Mar 06, 2023 09:58 HKT/SGT Read More
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan Eisai Mar 02, 2023 09:45 HKT/SGT Read More
